Multiple oncology updates highlighted how new molecular targeting is converging with precision trial design. Otsuka’s Voyxact (anti-APRIL) posted Phase III kidney-function slope data that suggests slowing or reversing decline in IgA nephropathy, pointing to antibody approaches that may transfer into broader immune-driven oncology-adjacent biology. In cancer biology, new studies mapped how tumors evade immune detection: researchers described a metabolic pathway linking high blood sugar and physical pressure inside tumors to immune escape mechanisms (Science Advances). In lung adenocarcinoma, new work identified transcriptional control nodes—such as C/EBPγ—for EMT, DNA repair, and therapy resistance. Taken together, the coverage emphasizes that next-generation oncology gains are increasingly tied to specific microenvironment signals and gene-regulatory dependencies, not only to drug targets in isolation.